SNOA
Sonoma Pharmaceuticals Inc. · NASDAQ
- Market cap
- $4.5M
Sonoma Pharmaceuticals Inc. (SNOA) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for SNOA, including 2 SEC filings and 1 market update. The most recent was published Nov 13, 2026.
Financial highlights
Full financials- Revenue, TTM
- $23.49M
- Revenue growth
- +38.7%
- Net income, TTM
- -$1.80M
- Net margin
- -7.6%
- Free cash flow, TTM
- -$2.79M
- Cash
- $4.61M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks23+50%
2026-05-242026-11-15
Mix690d
- SEC Filings4(67%)
- Other1(17%)
- Market1(17%)
Activity · 52 weeks4727 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECSEC Form S-3 filed by Sonoma Pharmaceuticals Inc.S-3 - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- NEWSSonoma Pharmaceuticals Reports Second Fiscal Quarter 2027 Financial Results, Delivering First-ever Net Income Before Income TaxTotal revenue increased 28% for the quarter and 41% for the six months ended September 30, 2026 compared to same periods last yearU.S. revenue increased 93% for the quarter and 113% for the six months ended September 30, 2026 compared to same periods last yearNet loss per share improved 97% for the quarter and 92% for the six months ended September 30, 2026 compared to same periods last yearNet income before taxes of $382,000 for the quarter and $52,000 for the six months ended September 30, 2026 BOULDER, CO / ACCESS Newswire / November 10, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabiliz
- SECSEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.10-Q - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECAmendment: SEC Form 8-A12B/A filed by Sonoma Pharmaceuticals Inc.8-A12B/A - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSEC Form 8-K filed by Sonoma Pharmaceuticals Inc.8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSonoma Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- NEWSSonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDATotal revenue increased 60% year over year to $6.4 millionNet loss per share decreased 88% compared to the prior-year quarterGross margin expanded to 40% as operating expenses remained stableFDA clearance and new global distributors support continued commercial growth BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results for its first fiscal
- SECSEC Form 10-Q filed by Sonoma Pharmaceuticals Inc.10-Q - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.DEF 14A - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.DEFA14A - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- INSIDERSEC Form 4 filed by Director Weigerstorfer Philippe4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Trombly Amy Moss4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)
- INSIDERSEC Form 4 filed by Director Mclaughlin John4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)
- INSIDERSEC Form 4 filed by Director Jacoby Vanessa4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Dvonch Jerome J4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)
- INSIDERSEC Form 4 filed by Controller Dal Poggetto John4 - Sonoma Pharmaceuticals, Inc. (0001367083) (Issuer)
- SECSEC Form S-8 filed by Sonoma Pharmaceuticals Inc.S-8 - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- NEWSSonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation SolutionBOULDER, CO / ACCESS Newswire / June 30, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader in hypochlorous acid (HOCl) technology, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn® Wound Irrigation Solution, including expanded claims, clearance for multiple use, and additional packaging configurations.Under this new clearance, Microdacyn Wound Irrigation Solution can be used under the supervision of a healthcare professional for cleansing, irrigating, moistening, debridement and removal of foreign material including microorganisms from exudating and/or dirty wounds, acute and chronic dermal
- SECSEC Form DEFA14A filed by Sonoma Pharmaceuticals Inc.DEFA14A - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSonoma Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSEC Form 424B5 filed by Sonoma Pharmaceuticals Inc.424B5 - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- NEWSSonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsRevenues increased 48% in Q4 2026 compared to Q4 2025, and 37% in FY 2026 compared to FY 2025United States revenues increased 194% in Q4 2026 compared to Q4 2025 and 117% in FY 2026 compared to FY 2025Net loss improved 25% in Q4 2026 compared to Q4 2025, and 8% in FY 2026 compared to FY 2025EBITDA loss improved 66% in Q4 2026 compared to Q4 2025, and 38% in FY 2026 compared to FY 2025 BOULDER, CO / ACCESS Newswire / June 16, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditi
- SECSEC Form 10-K filed by Sonoma Pharmaceuticals Inc.10-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSEC Form DEF 14A filed by Sonoma Pharmaceuticals Inc.DEF 14A - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
- SECSonoma Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Sonoma Pharmaceuticals, Inc. (0001367083) (Filer)
SNOA FAQ
10 questionsWhat does Sonoma Pharmaceuticals Inc. do?
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the...What is the latest news on SNOA?
In the last 30 days Quantisnow tracked 3 wire items for SNOA: 2 SEC filings and 1 market update. The most recent was published on November 13, 2026.What is SNOA revenue?
Sonoma Pharmaceuticals Inc. (SNOA) reported $23.49M of revenue for the twelve months ended Sep 30, 2026. That is up 38.7% from the year before. Revenue for fiscal 2026 was $19.53M.Is SNOA profitable?
No. Sonoma Pharmaceuticals Inc. reported a net loss of $1.80M for the twelve months ended Sep 30, 2026.How much cash and debt does SNOA have?
Sonoma Pharmaceuticals Inc. reported $4.61M in cash and cash equivalents on its most recent balance sheet in SEC filings.Where does SNOA stock trade?
Sonoma Pharmaceuticals Inc. (SNOA) is listed on NASDAQ.What sector and industry is SNOA in?
Sonoma Pharmaceuticals Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Sonoma Pharmaceuticals Inc. go public?
Sonoma Pharmaceuticals Inc. (SNOA) completed its IPO in 2007.What companies are similar to SNOA?
Notable peers in the same industry include ORGO (Organogenesis Holdings Inc.), IART (Integra LifeSciences Holdings Corporation), MDXG (MiMedx Group Inc), SNN (Smith & Nephew SNATS Inc.). Compare SNOA side-by-side with any of them on Quantisnow.How can I track SNOA on Quantisnow?
Quantisnow aggregates Sonoma Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNOA to receive live email and push alerts on every new disclosure.